ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Acrivon Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.69+0.05 (+3.05%)
Close on Oct 19, 2026
- Market cap
- $70.71M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -53.9% | |
| Return on assets | – | – | -47.7% | |
| Current ratio | – | – | 7.69 | |
| Diluted shares | – | – | 39M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Acrivon Therapeutics generated $216.07M from operations and spent $8.13M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$216.07M
Used
$8.13M
Capital expenditure$8.13M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$77.91M
- Cash generatingOperating cash flow above zero-$63.67M
- Return on assets improvedROA up on the prior year-58.3% → -39.6%
- Earnings backed by cashOperating cash flow above net income-$63.67M vs -$77.91M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose10.55 → 7.69
- No dilutionShare count did not rise34M → 39M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –